PPARs: a new target for neuroprotection.
paper
Cited
Public
Unavailable
- Authors
- Bordet, R; Gelé, P; Duriez, P; Fruchart, J-C
- Year
- 2006
- Journal
- Journal of neurology, neurosurgery, and psychiatry
- PMID
- 16484630
- DOI
- 10.1136/jnnp.2005.077495
- PMCID
- PMC2077704
PPAR agonists are potential neuroprotective drugs
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | 2015 | 25516156 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Current View on PPAR-α and Its Relation to Neurosteroids in Alzheimer's Disease and Other Neuropsychiatric Disorders: Promising Targets in a Therapeutic Strategy. | Żulińska S et al. | — | 2024 | → |
| Endocannabinoid-Binding Receptors as Drug Targets. | Gómez-Cañas M et al. | — | 2023 | → |
| Unveiling the Pharmacological and Nanotechnological Facets of Daidzein: Present State-of-the-Art and Future Perspectives. | Singh S et al. | — | 2023 | → |
| Astrocytes as a Therapeutic Target in Alzheimer's Disease-Comprehensive Review and Recent Developments. | Rodríguez-Giraldo M et al. | — | 2022 | → |
| Small molecules to perform big roles: The search for Parkinson's and Huntington's disease therapeutics. | Pérez-Arancibia R et al. | — | 2022 | → |
| The Efficacy of <i>Camelina sativa</i> Defatted Seed Meal against Colitis-Induced Persistent Visceral Hypersensitivity: The Relevance of PPAR α Receptor Activation in Pain Relief. | Lucarini E et al. | — | 2022 | → |
| The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study. | Parksepp M et al. | — | 2022 | → |
| PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. | Jamwal S et al. | — | 2021 | → |
| Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System. | Lago-Fernandez A et al. | — | 2021 | → |
| Role of Phytoconstituents as PPAR Agonists: Implications for Neurodegenerative Disorders. | Sanjay et al. | — | 2021 | → |
| 5-HT<sub>3</sub> Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface. | Fakhfouri G et al. | — | 2019 | → |
| Comprehensive review on the interaction between natural compounds and brain receptors: Benefits and toxicity. | Silva AR et al. | — | 2019 | → |
| Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration. | Neal M et al. | — | 2018 | → |
| Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans. | Blednov YA et al. | — | 2015 | → |
| Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. | Luchtman DW et al. | — | 2013 | → |
| [Dysfunction of the blood-brain barrier during ischaemia: a therapeutic concern]. | Bérézowski V et al. | — | 2012 | → |
| Expression Pattern of Peroxisome Proliferator-Activated Receptors in Rat Hippocampus following Cerebral Ischemia and Reperfusion Injury. | Wang H et al. | — | 2012 | → |
| Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds. | Nevin DK et al. | — | 2012 | → |
| New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury. | Neher MD et al. | — | 2012 | → |
| PPAR activation has dichotomous control on the expression levels of cytosolic and secretory phospholipase A2 in astrocytes; inhibition in naïve, untreated cells and enhancement in LPS-stimulated cells. | Sergeeva MG et al. | — | 2010 | → |
| Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease. | Kumar P et al. | — | 2009 | → |
| Novel therapies for increasing serum levels of HDL. | Toth PP | — | 2009 | → |
| Peroxisome proliferator-activated receptor and age-related macular degeneration. | Herzlich AA et al. | — | 2008 | → |
| Peroxisome proliferator-activated receptors: "key" regulators of neuroinflammation after traumatic brain injury. | Stahel PF et al. | — | 2008 | → |
| Administration of the peroxisomal proliferator-activated receptor gamma agonist pioglitazone during fractionated brain irradiation prevents radiation-induced cognitive impairment. | Zhao W et al. | — | 2007 | → |
| MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice. | Pialat JB et al. | — | 2007 | → |
| Novel peroxisome proliferator activated receptor-alpha agonists. | Fruchart JC | — | 2007 | → |